PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in CardioncologyVincenzo Quagliariello, Nicola Maurea, Irma Bisceglia et al.|Cancers|2023Cited by 42
Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer PatientsVincenzo Quagliariello, Nicola Maurea, Vienna Giordano et al.|International Journal of Molecular Sciences|2024Cited by 18
The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer PatientsVincenzo Quagliariello, Nicola Maurea, Massimiliano Berretta et al.|Cancers|2024Cited by 14
Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on ejection fraction reduction, myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity.Vincenzo Quagliariello, Nicola Maurea, Maria Laura Canale et al.|Journal of Clinical Oncology|2024Cited by 3
Effect of anti CTLA-4 and PD-1 monoclonal antibodies on systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models.Martina Iovine, Nicola Maurea, Vincenzo Quagliariello et al.|Journal of Clinical Oncology|2024Cited by 3